Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia

The success of tyrosine kinase inhibitors in treating chronic myeloid leukemia highlights the potential of targeting oncogenic kinases with small molecules. By using drug activity profiles and individual patient genotypes, one can guide personalized therapy selection for patients with resistance.

Detalles Bibliográficos
Autores principales: Eiring, Anna M, Deininger, Michael W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318205/
https://www.ncbi.nlm.nih.gov/pubmed/25316524
http://dx.doi.org/10.1186/s13059-014-0461-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318205/
https://www.ncbi.nlm.nih.gov/pubmed/25316524
http://dx.doi.org/10.1186/s13059-014-0461-8

Ejemplares similares